|
GB202102284D0
|
|
Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
|
|
GB202101048D0
|
|
Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
|
|
WO2021058454A1
|
|
Novel carrier particles for dry powder formulations for inhalation
|
|
WO2021052926A1
|
|
Agent for use in treatment or prevention of ophthalmic disorders
|
|
WO2020239953A1
|
|
Pyridopyrimidines derivatives as p2x3 inhibitors
|
|
WO2020239951A1
|
|
Amino quinazoline derivatives as p2x3 inhibitors
|
|
US2020330455A1
|
|
Method for treating neonatal opiod withdrawal syndrome
|
|
WO2020200918A1
|
|
Isochromene derivatives as phosphoinositide 3-kinases inhibitors
|
|
US2020289742A1
|
|
System comprising a pre-fillable syringe and a package for the pre-fillable syringe
|
|
WO2020187660A1
|
|
System comprising a pre-fillable syringe and a package for the pre-fillable syringe
|
|
WO2020136093A1
|
|
Process for preparing spherical agglomerates of timapiprant
|
|
WO2020114895A1
|
|
Laryngeal mask airway device and method for administering a medicament through a laryngeal mask airway device
|
|
WO2020088984A1
|
|
Apparatus to administer drugs to mechanically ventilated patients
|
|
CA3111158A1
|
|
Agent for treatment of dermatological disorders
|
|
BR132019015746E2
|
|
alcohol derivatives of 1-phenyl-2-pyridinyl alkyl as phosphodiesterase inhibitors
|
|
WO2020020957A1
|
|
Novel carrier particles for dry powder formulations for inhalation
|
|
TW202019923A
|
|
Tyrosine amide derivatives as Rho-kinase inhibitors
|
|
AR114926A1
|
|
AZAINDOL DERIVATIVES AS RHO-KINASE INHIBITORS
|
|
WO2019207106A1
|
|
Production of nerve growth factor (ngf) and of muteins thereof
|
|
BR112020021342A2
|
|
A THERAPEUTIC COMBINATION UNDERSTANDING A LUNG SURFACTANT AND A STEROID FOR PROPHYLAXIS IN DBP
|
